LHSC and Lawson announce world first treatment of localized prostate cancer
LONDON, ON, April 24, 2013 /PRNewswire/ – A world first procedure performed at
London Health Sciences Center (LHSC) and facilitated by research at
Lawson Health Research Institute (Lawson) provides a new minimally
invasive treatment option for patients with localized prostate cancer.
The treatment – transurethral magnetic resonance (MR) guided ultrasound
ablation for prostate cancer – utilizes a new ablation device that uses
thermal ultrasound therapy with real-time MR image guidance to
eliminate cancer cells in the prostate gland. Physicians have a 360
degree viewing angle that allows the whole prostate gland to be treated
in one session and with greater accuracy.
“This represents a significant advance in the management of prostate
cancer,” said Dr. Joseph Chin, chief, surgical oncology, LHSC.
“Magnetic resonance image guidance allows us to target prostate tissue,
using ultrasound energy without harming healthy tissue outside of the
While conventional treatments for localized prostate cancer, including
radiation therapy and surgery, provide good control of disease, they
leave men with significant long-term complications which can reduce the
patient’s quality of life. This new treatment option will reduce these
complications and can also benefit patients who have a smaller amount
of cancer that is less likely to spread.
Brian Danter, 62, a youth pastor from Windsor, Ontario, has lived with
prostate cancer for five years and is the second patient to be treated
in the study. “I was fortunate my cancer was found early and there was
only a small amount – about the size of a pencil dot,” says Danter.
Because the cancer was small, he and his health team chose to monitor
the cancer rather than proceed with more radical treatment options.
With this new treatment option available at LHSC, Danter seized the
opportunity to be rid of his cancer. “I was told I would not die from
my cancer, but now I am hopeful I will be cancer free.”
The world first procedure was done as part of a clinical trial approved
by Health Canada and sponsored by Profound Medical Inc., to evaluate
the safety and feasibility of the new ablation device to destroy
prostate tissue. Similar procedures have been done in an experimental
setting where the prostate was removed surgically immediately after the
treatment in order to examine the treatment effects. With the new
procedure, the prostate is not removed and the longer term effects of
the treatment will be monitored on both the patient and prostate.
The clinical trial will treat a total of 30 patients with localized
prostate cancer. The patients will be followed for one year to check on
the progress of the treatment and any side-effects, monitor indicators
of quality of life and signs of residual prostate cancer. Additionally,
the same patients will be followed annually for up five years to
collect data related to treatment effectiveness.
“We hope the clinical trial will show that this system can provide an
effective and minimally invasive treatment for localized prostate
cancer, with minimal side effects,” adds Chin.
About London Health Sciences Centre
London Health Sciences Centre has been at the forefront of medicine in
Canada for 138 years and offers the broadest range of specialized
clinical services in Ontario. Building on the traditions of its
founding hospitals to provide compassionate care in an academic
teaching setting, London Health Sciences Centre is home to Children’s
Hospital, University Hospital, Victoria Hospital, the Kidney Care
Centre, two family medical centres, and two research institutes -
Children’s Health Research Institute and Lawson Health Research
Institute. As a leader in medical discovery and health research, London
Health Sciences Centre has a history of over 65 international and
national firsts and attracts top clinicians and researchers from around
the world. As a regional referral centre, London Health Sciences Centre
cares for the most medically complex patients including critically
injured adults and children in southwestern Ontario and beyond. The
hospital’s nearly 15,000 staff, physicians, students and volunteers
provide care for more than one million patient visits a year. For more
information visit www.lhsc.on.ca
SOURCE London Health Sciences Centre